SCHEMBL639835

SCHEMBL639835

CCCCc1ccc2c(c1C(=O)[O-])Cc1ccccc1O2.CCCCc1ccc2c(c1C(=O)[O-])Cc1ccccc1O2.[Ni+2]

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
CYSLTR2 Q9NS75 6/20 0.34
CYSLTR1 Q9Y271 6/20 0.34
KMT2A Q03164 2/20 0.33
MAPT P10636 1/20 0.33
CYP1A1 P04798 1/20 0.33
MEN1 O00255 1/20 0.33
BID P55957 3/20 0.33
MCL1 Q07820 3/20 0.33
BCL2L1 Q07817 2/20 0.33
BAK1 Q16611 2/20 0.33
KAT8 Q9H7Z6 2/20 0.33
PPARG P37231 1/20 0.33
PPARA Q07869 1/20 0.33
EP300 Q09472 1/20 0.33
KAT2A Q92830 1/20 0.33
KAT2B Q92831 1/20 0.33
KAT5 Q92993 1/20 0.33
SAE1 Q9UBE0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL672342 0.98 MAOA (0.37) MAOAMAOBCYSLTR2CYSLTR1KMT2A
SCHEMBL672929 0.98 MAOA (0.37) MAOAMAOBCYSLTR2CYSLTR1KMT2A
SCHEMBL153269 0.98 MAOA (0.37) MAOAMAOBCYSLTR2CYSLTR1KMT2A
Potassium Ion SCHEMBL185380 0.98 MAOA (0.37) MAOAMAOBCYSLTR2CYSLTR1KMT2A
SCHEMBL11418926 0.98 MAOA (0.37) MAOAMAOBCYSLTR2CYSLTR1BID
SCHEMBL15157823 0.98 MAOA (0.37) MAOAMAOBCYSLTR2CYSLTR1KMT2A
SCHEMBL673639 0.98 MAOA (0.37) MAOAMAOBCYSLTR2CYSLTR1KMT2A
Zinc Ion SCHEMBL180553 0.98 MAOA (0.37) MAOAMAOBCYSLTR2CYSLTR1KMT2A
SCHEMBL8715449 0.98 MAOA (0.37) MAOAMAOBCYSLTR2CYSLTR1KMT2A
SCHEMBL671989 0.98 MAOA (0.37) MAOAMAOBCYSLTR2CYSLTR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3969490-B1 MODIFIED HIGH-CIS POLYBUTADIENE POLYMER, RELATED METHODS AND TIRE COMPONENTS BRIDGESTONE CORP (JP) 2026-03-25 EP disclosed
US-20250389555-A1 MODIFIED HIGH-CIS POLYBUTADIENE POLYMER, RELATED METHODS AND RUBBER COMPOSITIONS BRIDGESTONE AMERICAS TIRE OPERATIONS, LLC (US) 2025-12-25 US disclosed
US-12410263-B2 Modified high-Cis polybutadiene polymer, related methods and rubber compositions BRIDGESTONE AMERICAS TIRE OPERATIONS, LLC (US) 2025-09-09 US disclosed
US-12264232-B2 Modified high-cis polybutadiene polymer, related methods and tire components BRIDGESTONE CORPORATION (JP) 2025-04-01 US disclosed
US-20250066516-A1 HYDROGENATED POLYBUTADIENE POLYMERS AND RUBBER COMPOSITIONS INCORPORATING SAME BRIDGESTONE CORPORATION (JP) 2025-02-27 US disclosed
CN-113825777-B Modified high cis polybutadiene polymers, related methods and tire components 株式会社普利司通 2025-01-28 CN disclosed
EP-4495146-A2 MODIFIED HIGH-CIS POLYBUTADIENE POLYMER, RELATED METHODS AND RUBBER COMPOSITIONS Bridgestone Americas Tire Operations, LLC (US) 2025-01-22 EP disclosed
EP-4457250-A1 HYDROGENATED POLYBUTADIENE POLYMERS AND RUBBER COMPOSITIONS INCORPORATING SAME Bridgestone Corporation (JP) 2024-11-06 EP disclosed
EP-3966259-B1 MODIFIED HIGH-CIS POLYBUTADIENE POLYMER, RELATED METHODS AND RUBBER COMPOSITIONS BRIDGESTONE AMERICAS TIRE OPERATIONS LLC (US) 2024-10-30 EP disclosed
CN-118574860-A Hydrogenated polybutadiene polymer and rubber composition containing the same 株式会社普利司通 2024-08-30 CN disclosed
WO-2011047021-A1 PROCESSES FOR PREPARATION OF CYCLIC ACYCLIC DIENE COPOLYMER AND RUBBER COMPOSITION BRIDGESTONE CORPORATION (JP) 2011-04-21 WO disclosed
US-20100137520-A1 Branched Polymers and Methods for Their Synthesis and Use BRIDGESTONE CORPORATION (JP) 2010-06-03 US disclosed
US-7585805-B2 polymerization catalyst containing e.g.a combination or reaction product of triisobutylaluminum an alkylating agent, Ni(II) neodecanoate borate as nickel compound, trifluoride/n-hexanol complex as F2 compound and tin tetrachloride as Cl2 compound to polymerize 1,3-butadiene to cis-1,4-polybutadiene BRIDGESTONE CORPORATION 2009-09-08 US disclosed
EP-2066735-A2 BRANCHED POLYMERS AND METHODS FOR THEIR SYNTHESIS AND USE Bridgestone Corporation (JP) 2009-06-10 EP disclosed
US-20080255327-A1 addition polymerization of conjugated polyene monomer in the presence of polymerization catalysts comprising a mixture of a nickel-containing compound, an alkylating agent, a fluorine-containing compound, a carboxylic acid and an alcohol; controlling gelation, branching and molecular weight; efficiency BRIDGESTONE CORPORATION (JP) 2008-10-16 US disclosed
WO-2008045372-A2 BRANCHED POLYMERS AND METHODS FOR THEIR SYNTHESIS AND USE BRIDGESTONE CORPORATION (JP) 2008-04-17 WO disclosed
US-20070117942-A1 Nickel-based catalyst composition BRIDGESTONE CORPORATION 2007-05-24 US disclosed
EP-1788003-A1 Nickel-based catalyst composition Bridgestone Corporation (JP) 2007-05-23 EP disclosed
US-6699813-B2 COMPOSITION THAT IS COMBINATION OF OR REACTION PRODUCT OF LANTHANIDE COMPOUND, ALKYLATING AGENT, NICKEL-CONTAINING COMPOUND, AND OPTIONALLY HALOGEN-CONTAINING COMPOUND THAT INCLUDES ONE OR MORE LABILE HALOGEN ATOMS BRIDGESTONE CORPORATION (JP) 2004-03-02 US disclosed
US-20030176276-A1 Lanthanide-based catalyst composition for the manufacture of polydienes BRIDGESTONE CORPORATION (JP) 2003-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250389555-A1 MODIFIED HIGH-CIS POLYBUTADIENE POLYMER, RELATED METHODS AND RUBBER COMPOSITIONS MALT1, INO80C, RTCB MAOA 3771/4885MAOB 2373/4885CYSLTR2 2032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.